Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel E Furst

Showing results (461-470 of 477) with videos related to

Pageof 48
Sort By:
Seminars in Arthritis and Rheumatism|January 13, 2015
Antinuclear antibody-negative systemic sclerosisGloria A Salazar, Shervin Assassi, Fredrick Wigley, et al.
Arthritis Care & Research|April 5, 2012
2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisJasvinder A Singh, Daniel E Furst, Aseem Bharat, et al.
The Lancet. Rheumatology|December 30, 2021
Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trialLorinda Chung, Cathie Spino, Richard McLain, et al.
Journal of Scleroderma and Related Disorders|April 7, 2022
Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definitionCosimo Bruni, Maya H Buch, Daniel E Furst, et al.
Seminars in Arthritis and Rheumatism|June 27, 2026
Development of a single‑item patient‑reported measure of treatment side‑effect burden in clinical trials of rheumatic and musculoskeletal diseases using stakeholder input and large language model refinementDorthe B Berthelsen, Ben Horgan, Lee Simon, et al.
Annals of the Rheumatic Diseases|December 13, 2016
Update of EULAR recommendations for the treatment of systemic sclerosisOtylia Kowal-Bielecka, Jaap Fransen, Jerome Avouac, et al.
Arthritis Care & Research|November 5, 2011
Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exerciseJaap Fransen, Sindhu R Johnson, Frank van den Hoogen, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 26, 2019
Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled TrialDinesh Khanna, Cathie Spino, Sindhu Johnson, et al.
Arthritis Research & Therapy|January 22, 2016
Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patientsMinghua Wu, Shervin Assassi, Gloria A Salazar, et al.
Rheumatology (Oxford, England)|June 6, 2018
The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohortsDane H Dougherty, Linda Kwakkenbos, Marie-Eve Carrier, et al.
Pageof 48

Showing results (461-470 of 477) with videos related to

Sort By:
Pageof 48
Seminars in Arthritis and Rheumatism|January 13, 2015
Antinuclear antibody-negative systemic sclerosisGloria A Salazar, Shervin Assassi, Fredrick Wigley, et al.
Arthritis Care & Research|April 5, 2012
2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisJasvinder A Singh, Daniel E Furst, Aseem Bharat, et al.
The Lancet. Rheumatology|December 30, 2021
Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trialLorinda Chung, Cathie Spino, Richard McLain, et al.
Journal of Scleroderma and Related Disorders|April 7, 2022
Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definitionCosimo Bruni, Maya H Buch, Daniel E Furst, et al.
Seminars in Arthritis and Rheumatism|June 27, 2026
Development of a single‑item patient‑reported measure of treatment side‑effect burden in clinical trials of rheumatic and musculoskeletal diseases using stakeholder input and large language model refinementDorthe B Berthelsen, Ben Horgan, Lee Simon, et al.
Annals of the Rheumatic Diseases|December 13, 2016
Update of EULAR recommendations for the treatment of systemic sclerosisOtylia Kowal-Bielecka, Jaap Fransen, Jerome Avouac, et al.
Arthritis Care & Research|November 5, 2011
Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exerciseJaap Fransen, Sindhu R Johnson, Frank van den Hoogen, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 26, 2019
Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled TrialDinesh Khanna, Cathie Spino, Sindhu Johnson, et al.
Arthritis Research & Therapy|January 22, 2016
Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patientsMinghua Wu, Shervin Assassi, Gloria A Salazar, et al.
Rheumatology (Oxford, England)|June 6, 2018
The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohortsDane H Dougherty, Linda Kwakkenbos, Marie-Eve Carrier, et al.
Pageof 48